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Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion,
which is frequently encountered in clinical practice. Skin barrier dysfunction leads to enhanced skin
irritability to non-specific stimuli and epicutaneous sensitization. In the lesion site, a further
inflammation-related reduction in skin barrier function, enhanced irritability and scratching-related
stimuli deteriorate eczema, leading to vicious cycle of inflammation. The current strategies to treat AD
in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use
of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii)
topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of
apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines
present recommendations to review clinical research articles, evaluate the balance between the ad-
vantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes
with respect to several important points requiring decision-making in clinical practice.
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Atopic dermatitis (AD) is frequently encountered in clinical
practice. Descriptions regarding medical activities in the present
guidelines reflect an aim and goal in the current strategies to treat
AD in Japan from the perspective of evidence-based medicine2.
They can be utilized as a material for evaluations of decision-
making in clinical practice. Attending physicians must make a2 Generally, the manuscripts published by the end of December, 2015 were
reffered.
vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
N. Katoh et al. / Allergology International 69 (2020) 356e369 357final decision in cooperation with patients so that their values and
preferences are reflected.
1.1. Disclaimer
If the contents of medical activities based on an individual's
circumstances differ from those stated in the present guidelines,
they may not be checked, or the experience of healthcare pro-
fessionals may not be denied. In contrast, even if the contents
stated in the present guidelines are not performed, the re-
sponsibilities of physicians may not be pursued. Use of these
guidelines as a basis for use in medical disputes or in medical liti-
gation deviates from their original purpose.
Some evidence (Japan, other countries)-based therapies with
drugs that are not covered by health insurance (unapproved drugs)
are described in the guidelines, with the grade of recommendation.
The idea that drugs or therapies described in the guidelines are
available in clinical practice is not correct. This also applies to the
use of drugs of which contraindications or careful administration is
described in the package inserts. Even if unapproved drugs are
described in the guidelines, restrictions are not eliminated. Indi-
vidual drugs should be managed based on the contents of the
package insert or based on the latest information regarding safety.
2. Definition, pathogenesis, epidemiology, diagnosis, severity
2.1. Definition of atopic dermatitis: concept of disease
AD is a pruritic eczematous dermatitis; its symptoms chroni-
cally fluctuate with remissions and relapses. Most individuals with
AD have atopic diathesis (Atopic diathesis).
AD is an eczematous skin disease characterized by symmetrical
distribution, and the skin areas typically affected vary depending
on age.1,2 AD may develop during infancy or early childhood and
may lead to remission during childhood; however, AD may become
chronic in some cases with repeated relapses without remission,
and present with characteristic eczematous lesions that persist
until adulthood.
(i) personal or family history (asthma, allergic rhinitis and/or
conjunctivitis, and AD); and/or (ii) predisposition to over-
production of immunoglobulin (Ig)E antibodies. The presence of
allergy is not always necessary for the definition of AD. This differsFig. 1. Stratum corneum barrifrom allergic rhinitis for which the presence of allergy is mandatory
for diagnosis.3 Urticaria is not consideredwhen investigating family
andmedical history. Total serum IgE levels and allergen-specific IgE
antibody levels are considered as disease markers that tend to
produce IgE antibodies. As total IgE level increases in response to
disease activity, it is often low in patients with mild AD. In mild AD,
the allergen-specific IgE antibody level can be a marker of disease.2.2. Pathophysiology
AD is a multifocal disease with multiple etiologies. Different
etiologies are involved in the pathogenesis of ADwithin the context
of atopic diathesis and hypersensitivity reactions of organs
including skin that may be caused by causative factors (physical
constitution) and the vulnerability of barrier functions. The fact
that there is no hierarchy among those etiologies contributes to the
diversity of symptoms or phenotypes of AD.
2.2.1. Skin hypersensitivity - abnormalities of the horny cell
layer
The stratum corneum forms a barrier contributing to the pre-
vention of leakage of body fluids, retention of internal water within
the cell layers, and contributes to biological defense (Fig. 1, 2). If the
barrier function of the horny cell layer is dysfunctional, skin irri-
tability to non-specific stimuli is enhanced, and allergen sensiti-
zation and inflammation are likely to occur.4 Intercellular lipids of
the stratum corneum are mainly composed of ceramide, choles-
terol, and free fatty acids, and in the case of AD, the function of the
intercellular lipids of the stratum corneum deteriorates due to an
abnormal decrease of ceramide content, and themoisture retention
capacity is impaired.5,6 The horny cell layer consisting of keratin
and filaggrin is structurally robust. Filaggrin loss-of-function mu-
tation and filaggrin deficiency associated with inflammation have
been observed in AD.7,8
2.2.2. Mechanisms involved in inflammation (Fig. 2)
A decline in skin barrier function may allow allergens to easily
penetrate the skin. Allergens, which are foreign (non-self) mole-
cules, are eliminated by immunization and allergic reactions.
Allegens, such as the dust mite allergen, as well as proteiner and epidermal barrier.
Fig. 2. Pathogenesis of atopic dermatitis. FLG, filaggrin; IgE, immunoglobulin E; IL, interleukin; ILC, innate lymphoid cells; MDC, macrophage-derived chemokine; TARC, thymus and
activation-regulated chemokine; Th, T helper; TSLP, thymic stromal lymphopoietin.
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tivity. Helper T cells can be divided into Th1 and Th2 cells. Th1
cells have been demonstrated to be involved in cell-mediated
immunity, while Th2 cells are mainly associated with allergic re-
actions. Interleukin (IL)-33, IL-25, and thymic stromal lympho-
poietin (TSLP) produced by epidermal keratinocyte are associated
with Th2 cell migration to the lesion. Serum thymus and
activation-regulated chemokine (TARC) levels are also used as a
marker of short-term progression.9 The type 2 immune response
leads to allergen-specific induction of IgE antibodies. Langerhans
cells and mast cells express the high affinity IgE receptor (Fc 3RI)
and release cytokines and chemical transmitters (e.g. histamine)
via binding of allergen-specific IgE to induce inflammation.
Th22 cells produce IL-22 after migrating to the skin; likely, via
regulation by activated cutaneous dendritic cells, which induces
epidermal acanthosis.10 S100 protein produced by epidermal
damage further activates lymphocytes.11
2.2.3. Pruritus
AD skin lesions release various substances (pruritogens),
including cytokines and chemokines (e.g. IL-31, IL-4, and TSLP), and
chemical mediators that induce pruritus. These substances act on
nerves and thereby induce itching, which ultimately leads to
scratching behavior. Scratching results in the further worsening of
dermatitis. Skin hypersensibility can be observed in chronic in-
flammatory conditions such as AD. Hypersensibility may be
partially caused by the extension of the cutaneous sensory nerve
fibers to immediately below the horny cell layer of the skin surface
due to dryness or inflammation.12 An abnormal hypersensitivity
reaction in which algesia or heat pain stimulation induces itching
has also been reported for AD.13 Besides dermatitis, visual and
auditory stimulation suggestive of itching, such as the skin
scratching sound, induces itching and becomes prominent in AD.14
Imbalances between the sympathetic nerve system and theparasympathetic nerve system, emotional and psychogenic factors,
and disturbances in life rhythm are associated with onset and
worsening of itch.15,16
2.3. Genetic factors
Some genes have been described as candidate genes associated
with AD: CTLA4, IL18, TLR9, CD14, CARD4, PHF11, TLR2, SCCE, MCC,
IL4R, GM-CSF, TIM1, CARD15, GSTT1, SPINK5, SCYA11, TGFb1, IL-13,
RANTES, IL4, and FCER1B.2In addition, 2q12 (IL1RL1/IL18R1/
IL18RAP), 3q21.33 (GLB1), 3q13.2 (CCDC80), 6p21.3 (MHC region),
7p22 (CARD11), 10q21.2 (ZNF365), 11q15.4 (OR10A3/NLRP10),
20q13 (CYP24A1/PFDN4) have been reported to be an AD-related
region based on genome-wide linkage analysis from Japanese
samples.17
2.4. Factors involved in onset and exacerbation
When considering clinical pathology, factors associated with
disease onset and worsening should be taken into account. In
addition to adherence to treatment, exposure to environmental
factors including allergens and stimuli in the work place and daily
environment, life-style factors, and temperature, in addition to
dysregulation of physiological changes in skin function are associ-
ated with maintenance and exacerbation of dermatitis. A feeling of
warmth, sweating, wool fibers, psychological stress, food, alcohol
drinking, and the common cold are considered to be particularly
important as induction and exacerbating factors of itch in AD. The
details relative to onset and exacerbating factors and their specific
measures will be discussed below.
2.5. Diagnostic criteria
Based on the “Definition and Diagnostic Criteria for AD” pre-
pared by the JDA, patients meeting three basic items are regarded
as having AD regardless of the severity of symptoms: (i) pruritus;
(ii) typical morphology and distribution of the eczema; and (iii)
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patients are regarded as having acute or chronic eczema, and di-
agnoses are made based on their age and courses. It is essential to
differentiate the disorders which should be ruled out in diagnosis of
AD and be familiar with the complications of AD. Internationally,
the diagnostic criteria prepared by Hanifin and Rajka in 198018 and
by U. K. Working Party19 are widely used.2.6. Characteristics of eruption
2.6.1. Infancy (younger than 2 years of age)
Eruptions usually initially develop on the cheek, forehead, or
head appearing as skin dryness followed by papules during early
infancy. With a slight delay after the occurrence of facial symptoms,
exudative erythema develops in intertriginous zones such as the
neck, axilla, cubital fossa, and the popliteal fossa, moreover, ery-
thema and papules also develop on the trunk and extremities.Table 1
Definition and diagnostic criteria for atopic dermatitis by the Japanese Dermato-
logical Association.
Definition
Atopic dermatitis is a pruritic, eczematous dermatitis; its symptoms chronically
fluctuate with remissions and relapses. Most individuals with atopic
dermatitis have atopic diathesis.
Atopic diathesis: (i) personal or family history (asthma, allergic rhinitis and/or
conjunctivitis, and atopic dermatitis); and/or (ii) predisposition to
overproduction of immunoglobulin E (IgE) antibodies.
Diagnostic criteria for atopic dermatitis
1. Pruritus
2. Typical morphology and distribution
(1) Diagnostic criteria for eczematous dermatitis
 acute lesions: erythema, exudation, papules, vesiculopapules, scales and
crusts
 chronic lesions: infiltrated erythema, lichenification, prurigo, scales and
crusts
(2) Distribution
 Symmetrical
Predilection sites: forehead, periorbital area, perioral area, lips,
periauricular area, neck, joint areas of limbs, trunk
 Age-related characteristics
Infantile phase: starts on the scalp and face, often spreads to the trunk
and extremities
Childhood phase: neck, the flexural surfaces of the arms and legs
Adolescent and adult phase: tendency to be severe on the upper half of
body (face, neck, anterior chest and back)
3. Chronic or chronically relapsing course (usually coexistence of old and new
lesions)
 More than 2 months in infancy
 More than 6 months in childhood, adolescence and adulthood
Definitive diagnosis of atopic dermatitis requires the presence of all three
features without any consideration of severity
Other cases should be evaluated on the basis of the age and clinical course with
the tentative diagnosis of acute or chronic, non-specific eczema.
Differential diagnosis (association may occur)
Contact dermatitis, seborrheic dermatitis, prurigo simplex, scabies, miliaria,
ichthyosis, xerotic eczema, hand dermatitis (non-atopic), cutaneous
lymphoma, psoriasis, immunodeficiency diseases, collagen diseases
(systemic lupus erythematosus, dermatomyositis), Netherton syndrome.
Diagnostic aids
Family history (bronchial asthma, allergic rhinitis and/or conjunctivitis, atopic
dermatitis), personal history (bronchial asthma, allergic rhinitis and/or
conjunctivitis), follicular papules (goose skin), elevated serum IgE level.
Clinical types (not applicable to the infantile phase)
Flexural surface type, extensor surface type, dry form in childhood, head/face/
neck/upper chest/back type, prurigo type, erythroderma type, combinations
of various types are common.
Significant complications
Ocular complication (cataract and/or retinal detachment): especially in patients
with severe facial lesions, Kaposi's varicelliform eruption, molluscum
contagiosum, impetigo contagiosa.
Cited from reference.12.6.2. Childhood/school-age (2e12 years old)
From early childhood to school age, eruptions on the face
decrease, instead, eruption is typically observed on the neck, axilla,
cubital fossa, popliteal fossa, inguinal area, wrist, and ankle. In se-
vere cases, eruptions extend to the face and limbs, while repeated
scratching leads to repeated erosions and blood crusts. Lichen
papule and prurigo may develop on the limbs. Dry skin- or goose
bump-like follicular papules may be observed on the trunk and
extremities.
2.6.3. Adolescence/adulthood (13 years and older)
After puberty, eruptions are more likely to develop on the upper
body including the face, neck, chest, and back. In addition, face and
neck involvement and a prurigo on the trunk and extremities may
be observed. In severe cases, eruptions extend all over the body
resulting in erythroderma.
2.6.4. Characteristics of eruption
The eruption presents morphological characteristics of both
eczema and dermatitis. Themanifestation can be divided into acute
and chronic lesions. Patients with AD are likely to have dry skin
(dried skin, xeroderma, dry skin, atopic skin) across all age groups.
This characteristic is not visible in absence of inflammation of the
skin; however, it is remarkable in the presence of dermatitis.
Eruptions immediately after acute onset, present with erythema
and papules. Some may have vesicles and erosion. Repeated
scratching results in thickened skin caused bymechanical irritation
forming lichenified lesions and prurigo nodularis.2.7. Severity assessment
Precise severity assessment is essential for appropriate selection
of treatment. While overall severity is assessed, assessment of the
severity of the local lesion (i.e. individual eruption) is also impor-
tant to select the topical drug to be applied locally.
2.7.1. Overall assessment of severity
There are several methods proposed for severity assessment.
The easiest method is to use the “Severity index” as outlined in the
“Guidelines for the Treatment of Atopic Dermatitis” developed by
the MHLW Research Group. According to this “Severity index”, the
severity of eruption is categorized into mild eruption and eruption
with severe inflammation, and is further subclassified into mild,
moderate, severe, and most severe depending on relative propor-
tion of the lesions to the body surface area. If there is an eruption
associated with strong inflammation, even partially, it is classified
as moderate or severe (Table 2). It is a simple and easy-to-use index
for guiding treatment.
Severity classification methods with verified statistical reli-
ability and validity include the Atopic Dermatitis SeverityTable 2
Severity index.
Mild: Only mild eruption are observed irrespective of the area.
Moderate: Eruption with severe inflammation are observed in less than 10% of
the body surface area.
Severe: Eruption with severe inflammation are observed in10% to <30% of the
body surface area.
Most severe: Eruption with severe inflammation are observed in 30% of the
body surface area.
Mild eruption: Lesions are seen chiefly with mild erythema, dry skin, or desqua-
mation. Eruption with severe inflammation: Lesion with erythema, papule, erosion,
infiltration, lichenification, etc. Modified fromMinistry of Health andWelfare, Japan.
[Guidelines for the Treatment of Atopic Dermatitis 2008] (in Japanese).
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Atopic Dermatitis (SCORAD) index,22 and the Eczema Area and
Severity Index (EASI).23 The SCORAD index and the EASI are used
internationally. The SCORAD index has been reported in many
English-language papers and has been frequently used in clinical
research and trials. The maximum score of the SCORAD Index is
103, and its score can be calculated using a dedicated website
(http://adserver.sante.univ-nantes.fr/Scorad.html). The EASI is
recommended by the Harmonising OutcomeMeasures for Eczema
(HOME), an international multi-professional group dedicated to
standardizing AD clinical research outcomes (http://www.
homeforeczema.org/index.aspx). The EASI score chart can be
downloaded from the dedicated website (http://www.
homeforeczema.org/resources.aspx), and assessment training is
available online. Either of the above methods can be selected,
however, it is recommended that the simple “Severity index” be
used for routine clinical practice and the international EASI or
SCORAD index for clinical research or trials.
2.7.2. Assessment of eruption severity
Selection of topical steroids, a key treatment, depends on “the
severity of individual eruption”.1 That is, a sufficiently potent
topical therapy is selected for severe eruption even though the
affected area is limited, while a potent topical therapy is not
necessary for a milder eruption even if effects are more extensive.
The severity of the eruption is categorized into 2 to 3 levels ac-
cording to the above-mentioned assessment methods.
2.7.3. Assessment of pruritus
Itching is the most important feature of AD. As it is difficult to
assess itching objectively, the visual analogue scale (VAS) and the
numeric rating scale (NRS) are often used to obtain a patient's
subjective assessment.24 In VAS, patients are instructed to mark
one point on a 100-mm long horizontal line in accordance with the
degree of pruritus, and the distance (mm) from the left end to the
marked point is evaluated as the pruritus scale score, regarding the
left end “no itch” as 0 and the right end “the worst imaginable itch”
as 100.
For the NRS, patients are instructed to rate verbally their itch
using an 11-point scale from 0 (“no itching”) to 10 (“the worst
imaginable itch”). Subjective itch and insomnia due to itching can
be assessed using the SCORAD index, and neither VAS nor NRS are
suitable indexes. A good correlation of these methods with itching
has been reported.24
2.7.4. Assessment by patients
The Patient Oriented Eczema Measure (POEM) is a severity
scale, which was specifically designed to measure severity by the
patient and/or patient's caregiver using a questionnaire (For
adults: https://www.nottingham.ac.uk/research/groups/cebd/
documents/methodological-resources/poem-for-self-
completion.pdf, For children: https://www.nottingham.ac.uk/
research/groups/cebd/documents/methodological-resources/
poem-for-proxy-completion.pdf).25,26 It is useful in sharing
treatment goals between the physician and patient as has been
shown to correlate with assessment by physicians. A self-
administered patient-oriented SCORAD index (PO-SCORAD) has
also been reported.27
2.7.5. Assessment of quality of life
The quality of life (QOL) of patients with AD is tends to decrease
because of itching, issues regarding appearance, and burden of
treatment, among others. To provide QOL-conscious treatment, a
QOL assessment questionnaire, which is verified to be statistically
valid, is used.For adult patients, the Skindex-16 and DLQI can be used as QOL
assessment questionnaires for cutaneous diseases including
AD28e30; their Japanese versions are currently available.
A Japanese version of the Children's Dermatology Life Quality
Index (CDLQI) is available for children.31 For younger children, a
caregiver, often the mother is the main provider of treatment in
many cases. As the burden borne by the caregiver is substantial,
questionnaires evaluating “Quality of life in Primary Caregivers of
children with Atopic Dermatitis” (QPCAD) (19 items)32 and its
abbreviated version QP9 (9 items)15 have been specifically devel-
oped to evaluate the QOL of primary caregivers. The Japanese
Culturally Modified Version of the CADIS (JCMV-CADIS),16 a modi-
fied and translated version of the Childhood Atopic Dermatitis
Impact Scale,33 in which the caregiver responds to questions
regarding the QOL of both the affected children and the caregiver,
adapted to Japanese patients, is also useful.
2.8. Useful biomarkers for diagnosis and severity assessment
(Supplementary Table 1)
2.8.1. Serum IgE levels
A high serum total IgE level is observed in patients with allergic
diseases, however, a clear cut-off cannot be established because its
distribution greatly overlaps with that of healthy individuals. In
patients with AD, a total serum IgE level of 500 IU/mL or higher is
commonly observed.34 Serum total IgE level may represent allergic
diathesis rather than short-term disease activity in AD. However, it
can be an indicator of long-term response in severe cases as the
high serum total IgE level decreases after several months of follow-
up.
In addition, patients with AD are often sensitized to multiple
allergens including mites, house dust, pollen, fungi, and food. These
allergens can be detected by specific serum IgE antibody tests and
the skin prick test, however, it should be noted that non-specific
sensitization is often observed, that is, the presence of positive
specific IgE antibodies is not always causally related to the exac-
erbation of symptoms. In examining the causal relation between
allergens and symptoms, an adequate medical interview is a
fundamental approach.
2.8.2. Peripheral eosinophil count
Peripheral eosinophilia is more significant in patients with AD
compared to other allergic diseases such as bronchial asthma or
allergic rhinitis. As the peripheral eosinophil count increases with
disease severity, it can be a marker for disease progression.
2.8.3. Serum lactate dehydrogenase level
Serum lactate dehydrogenase (LDH) level increases in more
severe cases, thus, it acts as a marker of disease progression. An
increase in LDH levels may reflect tissue damage caused by skin
inflammation, and it returns to normal level when eruption is
resolved. Nonetheless, in cases in which LDH levels remain
elevated, complications due to other diseases leading to tissue
damage should be suspected and a differential diagnosis should be
considered.
2.8.4. Serum thymus and activation regulated chemokine level
Thymus and activation regulated chemokine (TARC: CCL17) is a
ligand of the chemokine receptor CCR4 and induces Th2 cell
migration.35 Serum TARC in patients with AD increases consistently
with severity, and testing for TARC levels is covered by the national
insurance as it reflects disease progression more strongly than
either serum IgE levels, LDH levels, or peripheral eosinophil
counts.35,36 Moreover, patient education and treatment can be
reviewed using serum TARC levels as an index.37 However, test
values should be carefully interpreted because TARC levels are
Table 3
Rank of topical corticosteroids.
Strongest
0.05% clobetasol propionate
0.05% diflorasone diacetate
Very strong
0.1% mometasone furoate
0.05% betamethasone butyrate propionate
0.05% fluocinonide
0.064% betamethasone dipropionate
0.05% difluprednate
0.1% amcinonide
0.1% diflucortolone valerate
0.1% hydrocortisone butyrate propionate
Strong
0.3% deprodone propionate
0.1% dexamethasone propionate
0.12% dexamethasone valerate
0.1% halcinonide
0.12% betamethasone valerate
0.025% fluocinolone acetonide
Medium
0.3% prednisolone valerate acetate
0.1% triamcinolone acetonide
0.1% alclometasone dipropionate
0.05 clobetasone butyrate
0.1% hydrocortisone butyrate
0.1% dexamethasone
Weak
0.5% prednisolone
As of September 2016. Cited from reference1 with modification. In the guidelines
adopted in the USA, corticosteroids are classified into seven ranks (I, very high
potency; II, high potency; IIIeIV, medium potency; V, lower-medium potency; VI,
low potency; VII, lowest potency).40 In Europe, they are classified into four ranks
(very potent, potent, moderately, mild).41 When referring to international clinical
trial data, it must be considered that the rank classification of topical corticosteroids
differs from that in Japan.
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years of age.38
3. Treatment approaches
3.1. Goal of treatment
The goal of treatment is to reach and maintain a state in which
symptoms are absent or mild without being disturbed in daily ac-
tivities by the disease and drug therapy is not required. Even when
this level is not reached, the objective is tomaintain a state inwhich
symptoms are mild without rapid exacerbations that affect daily
activities.
3.2. Treatment measures
Treatment measures for AD basically consist of drug therapy,
skin care for physiological abnormalities in the skin and in-
vestigations/elimination of exacerbating factors based on its path-
ogenesis. These measures are important, and are adequately
combined for individual patients based on the grade of symptoms
and background.
Atopic dermatitis is a multifactorial disease involving genetic
predispositions. There is currently no treatment that can
completely cure this disease. However, in the lesion site, a further
inflammation-related reduction in skin barrier function, enhanced
irritability and scratching-related stimuli deteriorate eczema,
leading to viscous cycle of inflammation. Therefore, controlling
inflammation by drug therapy will also reduce AD-exacerbating
factors.
3.3. Drug treatment
3.3.1. Topical anti-inflammatory drugs
Currently, these agents are used to provide adequate attenua-
tion of inflammation in AD. The efficacy and safety of topical cor-
ticosteroids (TCS) and tacrolimus ointments (topical calcineurin
inhibitor) have been examined in numerous clinical studies.
Hydrocortisone was the first TCS developed in 1952 and has
been used as topical drug therapy for AD for over 60 years. Efficacy
and safety of TCS have been examined in many clinical studies.39
TCS are often used as a first-line anti-inflammatory topical agent
for both children and adults.
Tacrolimus ointment is an inhibitor of calcineurin. Proto-
picⓇointment 0.1% was approved and introduced as a second-line
anti-inflammatory topical drug in 1999, and ProtopicⓇointment
0.03% was approved and introduced for use in children in 2003.
Both are now approved and marketed in over 75 countries.
Other topical agents include non-steroidal anti-inflammatory
drugs (NSAIDs), which have an extremely weak anti-inflammatory
effect and are not an uncommon cause of contact dermatitis; in-
dications for their application is narrow. It is important to promptly
and effectively attenuate inflammation in AD; thus, combination
strategies of TCS and tacrolimus ointments should be considered as
a basis of treatment. The extent of inflammation should be appro-
priately understood by inspection and to adequately apply these
agents to a sufficient degree.
(1) Topical corticosteroids (TCS)
TCS are used as a basic drug in treatment of AD, and its intensity
(rank) should be fully comprehended in order to select the most
appropriate TCS, based on the severity of the individual lesions and
to use different dosage forms of topical steroids according to the
features and site of lesions in order to maximize their anti-in-
flammatory effects. Adequate instructions and education should be
given to patients to improve adherence.
If eruption is maintained stable with suitable treatment, AD can
be expected to achieve remission. It is important to use appropriate
TCS, to promptly proceed with remission induction therapy toreduce inflammation and itching, and to maintain remission by
concurrent use of moisturizing agents. Cases showing no
improvement in eruption even after a 4-week treatment with
topical drugs or severe cases should be referred to a dermatologist.
a) Use of TCS
Selection of rank. In Japan, TCS are generally classified into 5
ranks: strongest (Group 1), very strong (Group 2), strong (Group 3),
medium (Group 4), and weak (Group 5) (Table 3). It is important to
adequately select drugs at a rank that matches the severity of each
eruption and use them at the required volume for the required
period (Table 4).
Severe cases: primarily acute and progressive severe inflam-
matory lesions, retractable lesions such as lichenification, ery-
thema, multiple papules, multiple scratch scars, or prurigo
nodularis are observed. Use of a very strong or strong class TCS is
the first-line treatment.
Moderate cases: primarily inflammatory findings of moderate
or less severe erythema, scales, and a few papules, and scratch scar
are observed. Use of a strong or medium classes of TCS is the first-
line drug treatment.
Mild cases: primarily mild-dry skin, mild erythema, and scales
are observed, and the use of medium class or weak rank TCS is the
first-line drug treatment.
Slight cases: Primarily dryness with negligible inflammation are
observed. Use of a emollient is the first-line drug treatment.
Although there is no need to decrease the rank because of age, for
infants and children the duration of use should be carefully moni-
tored, as efficacy is likely to appear in a short time in these age groups.
Selection of vehicles. Vehicles, such as ointment, cream, lotion
and tape preparations, need to be selected based on lesion char-
acteristics/sites. Ointment should be basically selected in order to
Table 4
Severity of eruption and topical corticosteroid (TCS) application.
Severity Eruption TCS application
Severe Primarily severe swelling/
edema/infiltration or erythema
with lichenification, multiple
papules, severe scales, crusts,
vesicles, erosion, multiple
excoriations and pruriginous
nodules
Use of very strong or strong
rank TCS is the first-line
treatment. Strongest rank TCS
are also available for refractory
pruriginous nodules if sufficient
effects are not achieved by
applying very strong rank TCS
Moderate Primarily moderate erythema,
scales, a few papules and
excoriations
Use of strong or medium rank
TCS is the first-line treatment
Mild Primarily dryness, mild
erythema and scales
Use of medium or weak rank
TCS is the first-line treatment
Slight Primarily dryness with
negligible inflammation
Topical application of
medicines other than TCS
(emollients)
Cited from reference.1
TCS, topical corticosteroid.
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the oily sensation of ointment use reduces adherence to topical
preparations (e.g. summer), a cream base is sometimes selected
while avoiding the erosive surface or scratching marks. Lotion base
is basically used for scalp lesion. Use of tape preparations would be
considered for pruriginous lesions and lichenified lesions.
Way of application. i) Volume: A volume (~0.5 g) measuring
5 mm in diameter that is pushed out from a tube to an area be-
tween the tip and first joint of the second finger is appropriate for
two palms of British adults, that is, approximately 2% of the body
surface area of adults (fingertip unit)42 (Supplementary Table 2).
This may be adopted as a reference, considering the physical status
of Japanese individuals and the tube size of topical corticosteroids
available in Japan. On the other hand, the appropriate volume
would change according to some factors including skin constion
and vehicle of topicas agent.
ii) Frequency of application: As a rule, TCS should be applied
twice a day (morning and evening: after bathing) in cases of acute
exacerbation. When inflammation is reduced, the frequency of
applications should be decreased to once a day to induce remission.
Further evidence needs to be accumulated in order to determine
whether efficacy differs between twice-a-day and once-a-day ap-
plications. However, several randomized controlled studies and
systematic reviews reported no significant difference in efficacy
between twice-a-day and once-a-day applications.43 It is generally
recognized that even a once-a-day application exhibits potent ef-
fects. If the number of applications is low, the incidence of adverse
reactions may be low, thereby improving adherence. Therefore,
topical corticosteroids should be applied twice a day to control
acutely exacerbated eruptions for an early recovery. When the
condition subsides, topical corticosteroids should be applied once a
day to achieve remission.
b) Consideration for the use of TCS
Regions of application. The absorption rate of topical steroids
by skin region is 13.0 on the cheek, 6.0 on the neck and 42 on the
scrotum, with the extensor surface of forearm defined as having a
rate of 1.0.44 Such skin regions having a high drug absorption rate
require attentive monitoring for the development of local side ef-
fects due to TCS treatment, and prolonged use should be avoided.
For the face, medium class or lower raked TCS are generally used,
while drugs consistent with the severity rank are used for severe
dermatitis to introduce prompt remission, and then, drugs aregradually tapered or administered intermittently. Moreover, an
effort to transition from TCS to tacrolimus ointments is made.
Discontinuation of topical drug treatment. When attenuation
of inflammation symptoms is achieved, TCS should not be dis-
continued abruptly, they should be gradually tapered or adminis-
tered intermittently while maintaining remission. Topical drugs
can be discontinued, if possible, however, proactive therapy, as
discussed below, should be considered for patients with repeated
relapses.
If TCS are suddenly discontinued in adult patients after pro-
longed use on the face or genitals, erythema, flushing, edema,
papules, and pustules may appear and worsen.45 In such cases, the
patient should be referred to a dermatologist.
c) Side effects of TCS
Systemic side effects. While adrenal function suppression has
been reported in some cases after the use of strong TCS,46,47 adrenal
function suppression and growth disorders have not been observed
with the use of weak rank TCS.48,49 If these drugs are used appro-
priately, less systemic side effects and higher safety can be ex-
pected.
Local side effects. Skin atrophy, capillary dilatation, steroidal
acne, steroid flushing, trichopsis, and progression of microbes/fungi
and viral skin infection can occur in some cases, however, they can
also be resolved with drug discontinuation or appropriate treat-
ment. Skin atrophy has been reported after the long-term use of the
very strong class of TCS, when compared to similar use in healthy
subjects. There are no reports of serious side effects after prolonged
use of TCS, thus, most side effects are transient and can be resolved
with reduced frequency of topical application, with the exception of
lineae atrophicae of the skin. Rosacea-like dermatitis is a TCS-
induced side effect presenting erythema, capillary dilatation,
follicular papules, and pustules, and is mainly observed on the face
of adult patients after prolonged use of TCS. If the TCS is stopped
abruptly, erythema and edema may worsen.45 If these symptoms
are observed, the patient should promptly be referred to a
dermatologist.
(2) Tacrolimus
Tacrolimus inhibits the activity of intracellular calcineurin. It
reduces inflammation via an action mechanism that differs from
that of corticosteroids. Tacrolimus ointment can be expected to
show a high level of effectiveness for AD-related eruption, which
was difficult to treat with topical corticosteroids, considering
adverse reactions.
The efficacy of this drug depends on drug absorption: the site of
application and barrier function. It is recognized as a drug to be
frequently indicated for the eruption on the face and neck. How-
ever, there are restrictions for its application that differ from topical
corticosteroids: tacrolimus ointment cannot be applied to erosive
or ulcerative surfaces, and its drug efficacy is limited. This drug
must be administrated according to the “Guidance for the Appli-
cation of Tacrolimus Ointment in Patients with Atopic Derma-
titis”.50 Tacrolimus ointment is available at the following
concentrations: 0.1% for adults and 0.03% for children. It cannot be
selected for children aged 1 year or younger as its safety has not yet
been established for this age group. Its application should also be
avoided in lactating women.
a) Volume
A volume of 0.1 g (corresponding to a volume squeezed by 1 cm
from a 5-g tube commercially available in Japan) is appropriate for a
10-cm square. Based on the findings of a long-term observational
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ointment per session for adults was established as 5 g to avoid an
increase in its blood concentration and maintain its safety. In
accordance with the physical status, the maximum volume of a
0.03% ointment per use was established as 1 g for children aged
2e5 years (bodyweight, <20 kg), 2e4 g for those aged 6e12 years
(bodyweight, 20e50 kg) and a maximum of 5 g for those aged 13
years or older (bodyweight, 50 kg). The target volume of this
ointment per area measuring 10 cm 9 10 cm is 0.1 g (1-cm volume
pushed out from the 5-g tube commercially available in Japan).
b) Way of application
Irritative symptoms, such as a transient burning sensation and
hot flushes, often appear at the site of application. However, these
symptoms appear at the start of treatment, and most symptoms
disappear with improvements in eruption. This should be
explained to patients before the start of treatment. This ointment is
very effective for the face and neck, in which its percutaneous ab-
sorption is favorable. This ointment should be indicated when
conventional therapy with TCS is ineffective (e.g. sites in which
local adverse reactions to TCS are observed) or when physicians
hesitate to administrate TCS due to adverse reactions.
The efficacy of this ointment (0.1% for adults) for the trunk and
limbs may be similar to that of strong-class topical corticoste-
roids.50 When treating the site of severe eruption, which requires
potent drug efficacy, very-strong-class or stronger TCS should
initially be used to reduce eruption, as a rule. The regimen should
then be switched to tacrolimus ointment. The volume of TCS can be
decreased in many cases by combining them with this ointment. If
an improvement in eruption is achieved by this ointment, the in-
terval of application should be prolonged at an appropriate time.
This ointment should not be used in sites/eruption areas in
which blood transfer of this drug may increase and enhance irri-
tability, that is, mucosa/genital areas and erosive/ulcerative sur-
faces. Occlusive dressing technique and superposition methods
should not be adopted because they may increase the blood
transfer of this drug. When erosive/ulcerative surfaces are mark-
edly affected, the application of this ointment should be started
after the amelioration of the eruption using other topical drugs.
c) Adverse reactions
A burning sensation, pruritus and erythema have been identi-
fied as local adverse events. These symptoms decrease or disap-
pear with improvements in eruption in many cases. Furthermore,
the appearance of infectious diseases of the skin, such as sec-
ondary skin infections with bacteria and viral infections (e.g.
herpes simplex, molluscum contagiosum and verruca), must be
considered. Skin atrophy, which is observed with the longterm use
of TCS, has not been confirmed. Tacrolimus is detected in the
blood following its topical application. Individual differences have
been reported in blood levels of tacrolimus due to differences in
percutaneous absorption (application of 0.1% tacrolimus: 1 ng/
mL). Neither systemic adverse events nor toxicity related to blood
transfer has been confirmed. We should explain patients about
precautions for use written in its package insert, and should obtain
their consents.
(3) Proactive therapy
Proactive therapy is used to maintain remission via the appli-
cation of topical steroids or intermittent topical tacrolimus (e.g.
twice a week) to recurrently relapsed eruptions, in addition
following treatment in the acute phase, skin care with moisturizing
topical drugs is also introduced after remission. In contrast, reactive
therapy is used to control inflammation with anti-inflammatory
topical drugs on relapse.In AD, histological evidence of inflammatory cells is still present
despite the normal appearing skin following the resolution of
inflammation; inflammation can easily relapse due to external or
internal factors.51 In such cases, markers indicating disease pro-
gression, such as TARC, do not decrease to normal levels in many
cases. During this latent inflammation stage, proactive treatment
with anti-inflammatory topical drugs including TCS or topical
tacrolimus may prevent relapse of inflammation.52 However, it is
important to transition from successive application of anti-in-
flammatory topical drugs to proactive treatment based on labora-
tory data indicative of disease progression, such as TARC levels,
after the dermatitis has fully improved and there is no evidence of
itching or erythema, and in absence of any slight elevation of skin
on palpation. Moreover, dose, application range, and the time to
complete the treatment of topical drugs should be determined
individually for each patient. Development of side effects should be
also carefully monitored. Proactive treatment should be performed
in collaboration with a physician experienced in the evaluation of
cutaneous symptoms of AD or in the evaluation of cutaneous
symptoms in general. During proactive treatment, continuation of
daily skin care with moisturizing topical drugs is recommended.
3.3.2. Antihistamines
Controlling pruritus is important treatment approach in AD.
Efficacy of antihistamines has been examined in combination with
anti-inflammatory topical drugs such as TCS, tacrolimus ointments,
andmoisturizing drugs, and beneficial effects on reducing itch have
been reported in 75% of 26 randomized clinical trials (RCTs) con-
ducted in Japan and abroad. These RCTs studied the efficacy of
antihistamines in relieving itching as a primary endpoint, and the
some studies reported improvement of cutaneous symptoms, dose
reduction of TCS, lowered drug rank, and improvement of sIL-2R
and TARC levels. Therefore, the use of antihistamines is recom-
mended as an adjuvant therapy to anti-inflammatory topical
therapy for AD. There is no reliable evidence for the efficacy of
antihistamines alone in the treatment of AD, therefore, use of an-
tihistamines alone without combination with anti-inflammatory
topical drugs is not recommended.
Antihistamines include sedative antihistamines (first-genera-
tion) with relatively strong anticholinergic and sedative effects and
non-sedative antihistamines (second-generation) causing less
drowsiness and impaired performance (impaired concentration,
judgment, and reduced operating efficiency without subjective
sleepiness) and anticholinergic activity with less fatigue. Based on
the extent these central effects, of histamine H1 receptor occu-
pancy in the brain, antihistamines have been divided into 3 groups:
sedative, 50% or more occupancy; mildly sedative, 50e20%, and
non-sedative, 20% or less; the H1 receptor occupancy of almost
second-generation antihistamines has been demonstrated to be
30% or less53 (Supplementary Table 3). As there is no difference in
treatment efficacy between sedative and non-sedative anti-hista-
mines, it is recommended that a non-sedative antihistamine be
selected.54
According to the package insert of the antihistamine ketotifen,
this agent is contraindicated in patients with epilepsy or a history of
epilepsy, and careful administration of clemastine, hydroxyzine,
cetirizine, and levocetirizine is indicated for patients with convul-
sive disorders. Convulsions are reported as a serious side effect of
chlorpheniramine, cyproheptadine, and loratadine treatment.
Thus, special attention is needed when administrating these agents
to children.
3.3.3. Cyclosporin
The efficacy of cyclosporin for AD has been demonstrated in
many countries in Europe and the USA.55 It has been approved for
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patients with severe adult AD who do not respond to conventional
treatments, showing eruptionwithmarked inflammation involving
30% or more of the body surface area.56
The initial dose of this drug is 3 mg/kg per day. Its administra-
tion should be completed in 8e12 weeks. Factors such as ne-
phropathy, hypertension and infection must be considered during
therapy with cyclosporin. As the safety of its long-term adminis-
tration has not yet been established, it is important to promptly
switch cyclosporin therapy to conventional topical treatment after
the amelioration of symptoms. Intermittent administration
involving a 2-week or much longer period of discontinuation
should be performed if long-term administration is necessary.
3.3.4. Oral corticosteroids
A double-blind randomized controlled study has not yet been
conducted to investigate the effects of oral corticosteroids on AD.
However, these drugs have sometimes been used to induce the
remission of acute exacerbation or severe/the most severe condi-
tions. Although they are known to be effective, long-term oral
corticosteroid therapy induces various serious systemic adverse
reactions; therefore, longterm AD control with oral corticosteroids
is not recommended. If necessary, administration should be
completed in a short period.
3.3.5. Considerations regarding pregnant or breastfeeding
mothers
Dietary restrictions (elimination of food allergens) for pregnant
or breastfeeding mothers to prevent the onset of AD cannot be
recommended. There is the possibility that AD may be exacerbated
and transferred to the infant after ingestion of food allergens such
as eggs through breast milk, however, these infants should be
carefully diagnosed based on the results of food elimination and
food challenge tests (via breast milk).57
Administration of antihistamines during pregnancy which is
considered safe can be administered if it is deemed therapeutically
beneficial. Most antihistamines that have been demonstrated not to
increase the risk of congenital anomalies based on epidemiological
observational studies and meta-analyses belong to first-generation
agents. Among the second-generation antihistamines, loratadine
and cetirizine have been reported not to be associated with
congenital anomalies in epidemiology studies.58e60 However, it is
important to use these agents according to the information on
package inserts and the latest reports on safety.
As for administration of these drugs during breastfeeding, only a
minimal amount of drug will be transferred to breast milk. How-
ever, second-generation antihistamines are recommended consid-
ering the potential for irritability and drowsiness in infants caused
by first-generation sedative antihistamines. With regard to indi-
vidual drugs, careful consideration of the contents of package in-
serts and the latest information on safety profiles is also necessary.
During both pregnancy and breastfeeding, topical steroids are
considered safe, so they can be used without any concern about
effects on the fetus of infant. Although long-term use of high doses
of higher ranked topical steroids (300 g or more) may result in
lower birth weight, complications are unlikely to occur with
normal use.58
Standard TCS therapy shows low-level absorption in systemic
circulation, and neither congenital anomalies nor the influence on
fetal growth has been raised as an issue. However, we cannot rule
out the possibility that birthweight may be decreased by the3 In Europe, TCS are classified into four ranks (very potent, potent, moderately,
mild).41massive application of TCS classified as potent/very-potent3
groups according to the classification used in Europe (especially
300 g or more). Therefore, attention should be paid to the volume
of TCS used and fetal growth. Furthermore, it is important to
favorably control dermatitis before pregnancy in order to avoid
this anxiety. If the application of TCS to the breasts of lactating
women is necessary, care must be taken to prevent infants from
directly ingesting TCS.
3.4. Skin care
3.4.1. Topical moisturizers
In AD, the skin barrier functions and moisturizing factors are
impaired. The use of moisturizer products improve moisture con-
tent in the stratum corneum and leads to the prevention of allergen
invasion and relapse of dermatitis, as well as suppression of itching
by recovering and maintaining skin barrier functions.61,62 More-
over, skin care with moisturizers immediately after birth and
thereafter, decreases the risk of onset of AD.63,64
An essential aim of skin care for dry skin is topical administra-
tion of hydrophilic ointments (oil in water: O/W) with a high
moisture-retaining property or water-absorbing ointments (water
in oil: W/O) to supplement the reduction of the moisture-retaining
properties on the skin surface.
It is especially recommended to applymoisturizers immediately
after bathing. Topical moisturizers should be applied all over the
body including sites that appear to be normal. Continuous use of
moisturizer products even after achieving remission of dermatitis
with topical anti-inflammatory drugs is also useful to maintain the
remission.65
3.4.2. Bathing, showering and washing
In AD, besides the adhesion of topical drugs and body fluids (e.g.
sweat) to the lesions, sebum and colonization of infectious patho-
gens such as Staphylococcus aureusmay also adhere, and may act as
exacerbating factors of cutaneous symptoms. Therefore, keeping
the skin clean is important to maintain the skin's physiological
functions. In general, bathing and showering are encouraged to
clean skin and appropriate moisturizing and skin protective agents
and anti-inflammatory topical drugs are used if necessary. The
optimal bathing and cleaning procedure in AD varies depending on
the individual patient, season, and symptoms in the same patient.
(1) Temperature
The temperature of hot water in bathing/showering should be
set at about 38e40 C because the itching response is induced at a
skin temperature of 42 C or higher, while 36e40 C is the optimum
temperature for recovery of skin barrier functions.66e68 Water is
diffused and evaporated from the skin surface immediately after
bathing resulting in dry skin, thus, the skin should not be left
without the application of a moisturizing agent for an extended
time after bathing.
(2) Soap and/or detergent
Although there is no high quality evidence demonstrating the
efficacy of using soap or detergent for AD, symptoms have been
shown to improve without experiencing exacerbation in patients
who did not use soap with prolonged bathing in a case series
study of commonly used soap preparations.69 As the major
component of soap and/or detergent is surfactants, excessive
abuse of these products may exacerbate skin dryness. Moreover,
additives contained in detergent, such as pigment and perfume,
are believed to irritate the skin. Based on the above, the use of
soap and/or detergent may be useful to keep the skin clean,
however, skin conditions that vary according to age, site, and
season, type and usage of soap or detergent should be considered.
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severe cases, during dry seasons, and in those sensitive to strong
irritation by soap or detergents. In contrast, soap and detergents
should be used aggressively in patients with oily skin or for seb-
orrheic skin, in sites where ointment is applied every day, and in
sites exhibiting recurrent skin infections to avoid exacerbating
factors. Removal of residues on the skin should be removed using
a minimal degree of mechanical irritation, and adequate rinsing of
the skin in necessary to remove residual detergent is also
important.
3.5. Search for exacerbating factors and measures
3.5.1. Non-specific irritation
Non-specific irritation present in daily-life such as contact with
saliva, sweat, hair, and friction against clothes may exacerbate AD.
As even minor stimulation, including irritation from the rough
texture of clothes, such as fromwool, and contact from the tip of the
hair can induce itchiness on sensitive skin due to skin dryness or
eczema, appropriate measures should be taken, for example,
choosing suitable nonirritating clothing, cutting hair short, or tying
up hair.
In addition, the residues from shampoo, conditioner, and soap or
excessive use of these agents may induce irritant dermatitis, thus,
providing instructions on appropriate cleansing methods is
important.
Irritation from scratching is extremely important as an exacer-
bation factor of AD. In addition to dermatitis treatment to reduce
itch, cutting nails short, and wearing gloves, long sleeves and long
pants while sleeping, if necessary, so that scratching does not cause
skin damage, may be helpful in some cases.
3.5.2. Contact allergy
Contact allergy to topical drugs, cosmetics, perfume, metal,
shampoo, hair conditioners, and disinfectants may case progression
of eczema.70 When expected treatment efficacy for AD cannot be
achieved, when the distribution of eczema is not typical, and when
AD onset or progression has occurred recently in an adult patient,
complications due to contact allergy should be suspected. In such
cases, observe whether the eczema can be resolved by avoiding
contact with a potential causal agent, and confirm the diagnosis by
a patch test.
3.5.3. Food allergens
Food allergens may be present in patients with AD pathology,
especially during infancy. However, a systematic review has re-
ported that there is only weak evidence of the efficacy of an
allergen elimination diet in treating AD in children and adults
without any clear involvement of food allergy.71 The allergen
elimination diet presents nutritional issues associated with po-
tential growth and development impairment when undertaken
during childhood; thus, allergen elimination therapy should be
provided under the close surveillance of physicians. Except for
cases inwhich progression of AD due to a certain food is confirmed,
the elimination of a specific food because it is likely to become an
allergen is not recommended. In order to eliminate a specific food
from the diet, an allergen elimination test should be conducted
after adequate anti-inflammatory therapy for AD. If no improve-
ment is achieved in cutaneous symptoms even after anti-
inflammatory therapy with appropriate intensity and sufficient
doses of TCS, food allergens causing progression of eczema should
be identified. If AD is poorly controlled because of inadequate
topical therapy, making a definitive diagnosis will be difficult.
The involvement of food allergens should be determined with
reference to the results of interview to obtain detailed previousmedical history, skin tests, and blood tests, as well as the oral
challenge test after eliminating causal food. For example, clinical
symptoms alone or positive results to a specific IgE antibody alone
should not be used as a basis for diagnosis. If ingestion of certain
food is restricted because it is perceived to be a likely allergen, it can
be considered useful treatment for AD. AD is multifactorial, and
elimination of food allergens is an adjuvant therapy to drug ther-
apy, thus, it should be recognized that complete remission is not to
be expected with elimination of food allergens even after clarifying
the involvement of food allergens.
The American Academy of Pediatrics recommends the allergen
elimination diet for pregnant women in 2000. However, a sys-
tematic review of randomized comparative studies of allergen
elimination diets in pregnant or breastfeeding mothers conducted
between 2006 and 201272 reported that dietary restrictions with
the aim of eliminating allergens these women did not show any
efficacy in preventing the onset of AD in neonates or in infants up to
18 months of age. Furthermore, dietary restrictions may have a role
in limiting adequate weight gain during pregnancy and may
worsen nutritional status among children leading an increased risk
of immature births. Based on the above, dietary restrictions
(allergen elimination) in pregnant or breastfeeding mothers may
not be useful to prevent the onset of AD in children.3.5.4. Inhaled allergens
AD after infancy may experience progression due to the pres-
ence of environmental allergens such as mites, house dust, pollen,
and pet hair.73 Whether these allergens are to be considered
exacerbating factors for eruption should be carefully evaluated by
comprehensively considering medical history, environmental
changes, and changes in eruption features, and should include re-
sults of elimination tests and challenge tests, if possible, rather be
based on judgment of clinical symptoms alone, or by specific IgE
antibody titer, or skin prick test results. Similar to handling of food
allergens, eliminating environmental allergens is an adjuvant
therapy to pharmacotherapy and skin care; thus, it should be noted
that complete remission cannot be expected by eliminating these
allergens alone.
3.5.5. Useful specific IgE antibodies to inhaled allergens
Mites and pollen (from cedar, cypress, white birch, Alnus
japonica, Anthoxanthum odoratum, cocksfoot, and ragweed), ani-
mals (from pets including dogs, cats, other mammals, birds, and
hamsters), and fungi (from aspergillus and malassezia).
Measures for avoiding exposure to mites: Vacuum futons (Jap-
anese-style bedding, bed, or covers), use anti-mite sheets, prohibit
stuffed toys on beds, etc.
Pets: Give up pet(s), wash pet(s), prohibit pet(s) in the bedroom.
Pollen: Brush off all pollen on clothes when arriving home, wash
face. Use protective glasses and masks against pollens. Use oral
antihistamines, eye drops, and nasal sprays.
3.5.6. Sweating
Disturbances in perspiration as well as excess sweat remaining
on the skin surface exposed to high-temperatures and humidity
may worsen symptoms of AD. Malassezia-derived allergens found
in sweat residues on the skin surface that have not evaporated may
lead toworsening of symptoms.74 High-temperatures and humidity
on the skin surface occludes sweat pores and induces perspiration.
To protect the skin surface from having excessive sweat, and un-
dergarment made of breathable and low hygroscopic fabric should
beworn to avoid high-temperatures and humidity, and appropriate
measures such as showering, rinsing using running water, wiping
N. Katoh et al. / Allergology International 69 (2020) 356e369366with wet towels, and changing wet clothes after sweating should
be adopted.
Among patients with AD, some sweat normally, while others
produce moderate amounts (scanty sweat).75 Inspection and
palpation are helpful in determining whether a patient's sweating
is normal. Significant dryness of the skin, flushing, and heat sen-
sations are important findings indicating poor perspiration.
3.5.7. Bacteria and fungi
It is known that S. aureus is often detected in the lesion of pa-
tients with AD, and S. aureus may be an exacerbating factor of AD.
The role of bacteria in AD is largely unknown, however, bacterial
flora analysis of the skin has recently revealed its involvement in
clinical conditions. On the skin of children with AD, it has been
reported that the diversity of the bacterial flora of the skin de-
creases in the exacerbation phase, and the proportion of S. aureus
increases.76 The results of studies in animal models have shown
that abnormal bacterial flora including the presence of S. aureus
may induce AD-like dermatitis, and maintenance of normal bac-
terial flora with antibiotic treatment can inhibit the occurrence of
dermatitis.77
There have been no reports suggesting that administration of
oral antibiotics is effective for AD in the absence of infection, thus,
administration of oral antibiotics is not recommended.78
The potential involvement of fungi on the pathology and
worsening of AD has been suggested based on the results of
measuring specific IgE antibodies levels to candida or malassezia
and skin prick test results in patients with AD.79 However, a clear
correlation with the clinical conditions is still unknown. While
there are some reports showing that oral antifungal drugs are
effective for AD,80 topical antifungal drugs have been shown to
be effective for eruptions on the head and neck,81 there have
been no large-scale studies to date, thus, careful use is
recommended.
3.6. Psychosomatic involvement
It is well known empirically that AD can be worsened by stress.
AD is known to be associated with concomitant developmental
disorders such as attention deficit hyperactivity disorder; however,
such diagnosis is not helpful for treatment. When AD is poorly
controlled, psychological burden or secondary cognitive abnor-
malities can occur, however, these patients should not be perceived
as “special” by clinicians, and comprehensive treatment should be
provided to all patients with specific attention to psychosomatic
interaction.
3.6.1. Verification of drug therapy and patient adherence
Clinical features of ADmainly consist of a reduction of epidermal
barrier functions and allergic inflammation, to which scratching
contributes to induce a vicious circle of these symptoms; this cycle
cannot be interrupted without the elimination of itching through
appropriate drug therapy and improvement in treatment adher-
ence. As persistence of itching is a trigger of various secondary
physical or mental disorders and behavior abnormalities, intense
medical treatment and patient education on specific procedures
and implementation schedules are required. Careful patient edu-
cation is essential for prevention and to overcome misconceptions
associated with steroid treatment.
3.6.2. Understanding of stressor effects as exacerbating factors
Adolescents often experience progression of skin conditions
due to tension before school exams and lack of sleep. They also
often experience progression of skin exacerbation by fever or high
temperature. Such stressors are unavoidable factors; however,
these may be surmounted by stress management and behaviormodification, including changes in lifestyle habits, and relaxation
training.
3.6.3. Habitual scratching behavior
In situations where gain from illness can be obtained through
scratching behavior, habitual scratching is likely to occur because of
operant conditioning. When parents attempt to interrupt their
child's scratching behavior or in situations inwhich a conflict exists
among siblings, this can represent a potent instrument to draw
parental affection or attention from the rival. In severe patients,
anxiety and feelings of hopelessness regarding prognosis and
treatment are respondently conditioned through the repeated
paired presentation with the perception of itching sensation, thus,
patients are conditioned to instigate scratching behavior as a result
of a stimulus induced by anxiety, even in the absence of a conscious
itching sensation.
3.6.4. Patient education
Psychosomatic interventions with verified efficacy in RCTs have
reported results limited to behavioral science approaches, such as
behavioral therapy and cognitive behavioral therapy,82 while the
efficacy of psychoanalysis and counseling with attentive listening
have not been demonstrated. Implementing a comprehensive
approach to patient education using behavioral science techniques
such as appropriate drug therapy, supportive stress-reduction
training, including relaxation training and cognitive behavioral
therapy, behavioral therapy to stop habitual scratching, coaching to
improve therapy adherence, and motivational interviewing83 are
important.
3.7. Ultraviolet irradiation therapy
Ultraviolet (UV) therapy is considered for non-responders to
treatments with topical anti-inflammatory drugs, antihistamines or
moisturizers, as well as for patients with adverse reactions to
conventional treatments.1 Narrow-band ultraviolet B (NB-UVB)
irradiation therapy has been demonstrated to be effective in the
treatment of AD.84When administrating UV therapy, it is important
to initially consider whether it should be indicated, and it should
also be carefully performed by UV therapy-skilled physicians who
sufficiently understand the action mechanism, radiation dose,
acute skin disorders, deterioration of concomitant infectious dis-
eases, various long-term adverse reactions, including skin cancer,
and management methods. Ultraviolet irradiation therapy can be
used for children with psoriasis beginning at 10 years of age and
older, but is not recommended for children younger than 10 years
of age.85
3.8. Hospital care
It is difficult to induce remission in some severe patients in
whom the area of eruption is extensive with topical anti-
inflammatory agents. Hospital care is indicated for such patients.
Some severe patients exhibit acute exacerbation, whereas severe
dermatitis is chronically protracted in others. Both types of patients
should be admitted, with hospital care being more significant for
the latter.
In patients with chronically protracted severe dermatitis, there
are problems regarding disease activity, patient adherence and
aggravation factors as background factors. Hospital care may make
it possible to thoroughly perform intensive topical therapy with
isolation from the daily environment, establish a health-care
professionalepatient relationship of mutual trust, review trig-
gering factors/application methods/skin care and overcome these
problems in the early phase. Several hospitals reported that such
therapeutic interventions improved long-term prognoses after
patient discharge.86 In addition, it is often the case that patients can
Fig. 3. Algorithm for the management of atopic dermatitis.
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pected effects. For such patients with moderate to severe AD,
hospital care would be considered as required. Because continuous
topical treatment is required after the discharge of severe patients
for whom hospital care is indicated, it is essential to understand
their conditions and treatment methods. Therefore, the goal of
hospital care is to achieve the early remission of dermatitis by
intensive topical therapy and improve adherence through educa-
tional guidance.
3.9. Patient education
For AD mainly treated by topical therapy at outpatient clinics,
patients and their families have a key role in treatment. It is
essential that the patient's family properly understands the pa-
tient's clinical conditions and the treatment required in order to
improve adherence and achieve successful treatment.
Different approaches have been successful in many studies
regarding children, specifically, education by a multidisciplinary
medical team, group work by a specialized nurse, educational
hospital-stay for a short period of time, and education using online
videos.83,87e90 Other than above, websites and leaflets for young
patients have been developed and have been used as educational
tools for patients with AD in Japan.91 In clinical practice, these tools
should be selected as effective and feasible educational methods
taking into consideration the individual patient's characteristics
and medical care system provided at the treating facility. Confir-
mation on the use of topical drugs is important and appropriate
instructions should be provided before changing treatment, not
only during the treatment introduction phase, but also when the
expected efficacy of the therapy cannot be obtained.
3.10. Referral to a specialist
When no improvement of eczema is observed even after
implementing treatment in accordance with the present clinicalpractice guidelines for a period of about 1 month, referral to a
specialist or to a specialized facility should be considered.2
When prominent erythema, scars from scratching, erosion,
lichenification, or prurigo is observed, or a wide range of erythema
like erythroderma is observed, referral to specialist should be
considered. In addition, when infection to bacteria or virus is
concomitantly observed, or a detailed examination of the exacer-
bating factors including food allergies and contact allergy is
necessary, referral to specialist should also be considered.
3.11. Treatment procedures
Treatment procedures for AD are shown in Figure 3. After
making an accurate diagnosis and evaluating its severity, appro-
priate treatment methods should be combined in accordance with
the state of eruption. In the initial consultation, it is important to
explain the condition of AD and treatment methods to patients and
have a common understanding with them.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.alit.2020.02.006.
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